Other Services - Oncology preclinical CRO services

Cellomatics Biosciences is an Oncology CRO, providing expertise in supporting preclinical oncology projects. Alongside the ongoing development of disease models, our team of oncology specialists routinely perform high throughput drug screens, followed by a wide range of assays to measure certain biological responses that complement the hallmarks of cancer.The development of cancer arises from a dysregulation in cellular proliferation, which usually arises from inappropriate responses to external stimuli. Through the years, discovery of mutations in key oncogenes and tumour suppressor genes has been pivotal in characterising biological aberrancies that favour oncogenesis. For instance, many cancers harbour activating mutations in components of several survival pathways (e.g. PI3K and MAPK pathways) leading to constitutive signalling. Downstream effects include increased production of growth factors for inter and intracellular interactions, signalling cross talks and loss of response to inhibitory stimuli.